Saturday, Mar 17th

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.


Most Recent Related Stories...

Mississippi Legislature Passes Nation’s Strictest Abortion Ban On International Women’s Day

Mississippi Gov. Phil Bryant to sign nation's most restrictive abortion billMississippi lawmakers celebrated International Women’s Day on Thursday by passing a bill that would ban abortion...

New blood, urine tests can determine autism in children

New tests to detect autism in childrenBritish researchers believe they have developed the first blood and urine tests that can confirm autism...

Florida shooting reopens CDC gun research debate

CDC gun research debate opened up after Florida shootings A mass shooting at a Florida high school that left 17 people dead has reopened a debate in Congress...

Flu gone in a day? Japanese maker touts new drug

Flu drugs from Japan may cure in one day A single-dose pill that can halt the flu virus within a day. That's what Japanese drug maker...
America's # 1 Enemy
Tee Shirt
& Help Support!
TVNL Tee Shirt
Conserve our Planet
& Help Support!
Get your 9/11 & Media
Deception Dollars
& Help Support!
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!